RxDoctor Payments DataLook up a doctor →

Lauren Stegman, MD

Radiation Oncology · Phoenix, AZNPI 1730232448

Payments from drug & device makers

$10,491in general payments, 2019–2025

Across 415 payments — averaging $25.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$710
  • Elekta, Inc.$586
  • Novartis$537
  • Pfizer$461
  • Blue Earth Diagnostics$409
  • AbbVie$368
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$10,453100%
  • Education$170%
  • Entertainment$210%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)33$710
Elekta, Inc.6$586
Novartis29$537
Pfizer24$461
Blue Earth Diagnostics16$409
AbbVie18$368
Merck15$352
Novocure Inc.10$340
Lilly USA, LLC12$316
Bayer17$308
Daiichi Sankyo Inc.11$301
Incyte Corporation13$285
Johnson & Johnson8$274
Amgen12$236
Varian Medical Systems, Inc.2$217
Medtronic4$216
Progenics Pharmaceuticals, Inc.4$203
Icotec Medical Inc.2$200
Eisai Inc.7$174
Verity Pharmaceuticals Inc.8$170
Exelixis Inc.7$164
Genentech USA, Inc.6$160
Tempus AI, Inc1$145
E.r. Squibb & Sons, L.L.C.7$134
Sumitomo Pharma America, Inc.4$133
Seagen Inc.7$131
Sanofi6$130
Myriad Genetic Laboratories, Inc.6$129
Takeda Pharmaceuticals U.S.A., Inc.5$127
Stemline Therapeutics Inc.5$127
Accuray Incorporated1$119
Pharmacyclics LLC, An Abbvie Company5$113
Karyopharm Therapeutics Inc.5$111
Tersera Therapeutics LLC3$108
EMD Serono, Inc.5$102
Astellas Pharma US Inc5$97
Bristol Myers Squibb4$93
Ipsen Biopharmaceuticals, Inc5$92
Rigel Pharmaceuticals, Inc.4$86
Deciphera Pharmaceuticals Inc.3$81
Springworks Therapeutics, Inc.3$75
Boston Scientific4$66
Genmab U.S., Inc.2$64
GSK3$60
Regeneron Healthcare Solutions, Inc.2$59
Carbofix Spine Inc1$56
Pharmacosmos Therapeutics Inc.2$54
Adaptive Biotechnologies Corporation2$51
Sun Pharmaceutical Industries Inc.2$46
Servier Pharmaceuticals LLC2$45
Agios Pharmaceuticals, Inc.3$44
Mimedx Group, Inc.2$41
West Therapeutics Development, LLC2$40
Sobi, Inc1$40
Chiesi USA, Inc.2$38
AMAG Pharmaceuticals, Inc.2$38
Reflexion Medical, Inc.1$37
Portola Pharmaceuticals, LLC1$33
Amneal Pharmaceuticals LLC1$32
Myovant Sciences Inc.2$32

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,491 in reported general payments places this provider in the 80th percentile of 138 radiation oncology providers in Arizona.

See all radiation oncology providers in Arizona

Medicare billing

Part B allowed, 2024
$1,175,450
Medicare patients
386
Services billed
5,164

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix13$33,868
Pilocarpine Hcl11$1,308
Tamsulosin Hcl71$1,258
Pentoxifylline22$1,207
Bicalutamide27$1,176
Finasteride20$241

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Orgovyx$133$33,86813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 138 radiation oncology providers in Arizona.

Other radiation oncology in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →